GlobeNewswire Inc. · Mar 11, 2024
PH
NASDAQ · PHXM
PHAXIAM Therapeutics S.A.
Healthcare · Biotechnology
$3.10
Down-$0.17 (-5.20%)
Updated Sep 18, 2026, 1:00 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 19.86M
- P/E ratio
- -0.02
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 902
- Avg. volume
- 1.77K
Price performance
PHXM price history
1M range · 0 trading sessions · Daily adjusted prices
PHXM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest PHXM news
The latest Smart Investors Daily articles mentioning PHXM.
Stock researchCompany · Overview
PHXM research
Overview
Company profile and research snapshot.
Company profile
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Mar 11, 2024
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the Company. The Company will file a Form 15 with the Securities and Exchange Commission (“SEC”) to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in respect of the ADSs and the ordinary shares. The Company expects that the deregistration of the ADSs under the Exchange Act will become effective 90 days after the filing of the Form 15.
GlobeNewswire Inc. · Mar 5, 2024
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
GlobeNewswire Inc. · Mar 5, 2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
